Federal Bill Would Give FDA-Approved Botanical Drugs 12 Years of Market Exclusivity
核心洞察
The Advancing Botanical Drug Development Act of 2026, H.R. 10150, would give FDA-approved botanical drugs (搜索) 12 years of market exclusivity after qualifying approval.
The bill was introduced by Representative Lauren Boebert with Representative Derrick Van Orden and referred to the House Committee on Energy and Commerce (搜索).
The FDA has identified cannabis-derived products as developable under its botanical drug framework, so qualifying cannabis-derived medicines (搜索) could fall under the exclusivity period.
A newly introduced federal bill would provide FDA-approved botanical drugs (搜索) with 12 years of market exclusivity. The Advancing Botanical Drug Development Act of 2026, H.R. 10150, was introduced by U.S. Representative Lauren Boebert (R-CO) alongside Rep. Derrick Van Orden (R-WI) and has been referred to the House Committee on Energy and Commerce (搜索).
Under the proposal, a botanical drug approved through a qualifying new drug application submitted after the legislation takes effect would receive a 12-year period during which competing applications referencing or relying on the approved product could not become effective. The bill does not mention marijuana or cannabis specifically, but the FDA has identified cannabis-derived products as among those that can be developed under its botanical drug framework. The agency directs developers of cannabis-derived drugs to its Botanical Drug Development guidance and maintains a Botanical Review Team that works with developers of cannabis-related drug products. The exclusivity period could therefore apply to qualifying cannabis-derived medicines (搜索), particularly complex plant-based formulations containing multiple constituents, though not necessarily to every drug derived from cannabis, since the FDA generally excludes highly purified substances from its definition of botanical drug products.
The legislation states that botanical medicines face development challenges not generally encountered with conventional synthetic drugs, including variations in plant material, sourcing requirements, batch consistency testing and the need to characterize and standardize multiple constituents. Boebert said the measure is intended to create greater certainty for companies developing botanical medicines without weakening existing FDA requirements, adding that it would retain clinical trial, safety and effectiveness requirements. The proposal comes as the FDA opened a public request for information earlier this month seeking feedback on ways to advance botanical drug development. The agency says just four botanical products have received approval through its new drug application or biologics pathways to date.